WO2008121160A2 - Anticorps optimisés qui ciblent cd5 - Google Patents
Anticorps optimisés qui ciblent cd5 Download PDFInfo
- Publication number
- WO2008121160A2 WO2008121160A2 PCT/US2007/083247 US2007083247W WO2008121160A2 WO 2008121160 A2 WO2008121160 A2 WO 2008121160A2 US 2007083247 W US2007083247 W US 2007083247W WO 2008121160 A2 WO2008121160 A2 WO 2008121160A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antibodies
- cell
- cells
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
La présente invention concerne des anticorps qui ciblent CD19, les anticorps comprenant au moins une modification par rapport à un anticorps parent, la modification changeant l'affinité pour un FcgR ou changeant une fonction effectrice par comparaison avec l'anticorps parent. L'invention concerne également des procédés d'utilisation des anticorps.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86679306P | 2006-11-21 | 2006-11-21 | |
US60/866,793 | 2006-11-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008121160A2 true WO2008121160A2 (fr) | 2008-10-09 |
WO2008121160A3 WO2008121160A3 (fr) | 2009-01-22 |
Family
ID=39808822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/083247 WO2008121160A2 (fr) | 2006-11-21 | 2007-10-31 | Anticorps optimisés qui ciblent cd5 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008121160A2 (fr) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010126137A1 (fr) | 2009-05-01 | 2010-11-04 | 国立大学法人 東京大学 | Anticorps anti-cadhérine |
WO2011089211A1 (fr) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anticorps anti-cd133 et leurs procédés d'utilisation |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
US10000560B2 (en) | 2014-12-19 | 2018-06-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
WO2019234576A1 (fr) | 2018-06-03 | 2019-12-12 | Lamkap Bio Beta Ltd. | Anticorps bispécifiques dirigés contre ceacam5 et cd47 |
US10604561B2 (en) | 2016-09-16 | 2020-03-31 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
US10858686B2 (en) | 2010-05-27 | 2020-12-08 | Merck Sharp & Dohme Corp. | Method for preparing antibodies having improved properties |
US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
EP3831849A1 (fr) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Anticorps bispécifiques contre ceacam5 et cd47 |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
CN113105547A (zh) * | 2021-05-18 | 2021-07-13 | 福州迈新生物技术开发有限公司 | 抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用 |
US20210355230A1 (en) * | 2018-07-23 | 2021-11-18 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
EP3915641A1 (fr) * | 2020-05-27 | 2021-12-01 | International-Drug-Development-Biotech | Anticorps anti-cd5 et leurs procédés d'utilisation |
US20210369854A1 (en) * | 2017-11-29 | 2021-12-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd5+ cells |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
WO2022056459A1 (fr) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions et méthodes pour la modification du cd5 |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
WO2022130348A1 (fr) | 2020-12-18 | 2022-06-23 | Lamkap Bio Beta Ag | Anticorps bispécifiques dirigés contre ceacam5 et cd47 |
WO2022127844A1 (fr) * | 2020-12-17 | 2022-06-23 | 江苏先声药业有限公司 | Anticorps cd5 et son utilisation |
WO2022152185A1 (fr) * | 2021-01-12 | 2022-07-21 | 南京驯鹿医疗技术有限公司 | Anticorps entièrement humanisé ciblant cd5 |
WO2023242351A1 (fr) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Polythérapie d'anticorps bispécifiques dirigés contre ceacam5 et cd47 et anticorps bispécifiques dirigés contre ceacam5 et cd3 |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US11891432B2 (en) | 2018-03-15 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use |
WO2024040195A1 (fr) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditionnement pour l'ingénierie de cellules immunitaires in vivo |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060008883A1 (en) * | 2003-12-04 | 2006-01-12 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
WO2006105338A2 (fr) * | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Variants fc presentant des proprietes optimisees |
-
2007
- 2007-10-31 WO PCT/US2007/083247 patent/WO2008121160A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060008883A1 (en) * | 2003-12-04 | 2006-01-12 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
WO2006105338A2 (fr) * | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Variants fc presentant des proprietes optimisees |
Non-Patent Citations (4)
Title |
---|
ANTIN J H ET AL: "Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies." BLOOD 15 OCT 1991, vol. 78, no. 8, 15 October 1991 (1991-10-15), pages 2139-2149, XP002505318 ISSN: 0006-4971 * |
CIOCA D P ET AL: "Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia." LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K MAR 2002, vol. 16, no. 3, March 2002 (2002-03), pages 335-343, XP002505317 ISSN: 0887-6924 * |
PERS J O ET AL: "CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia." LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K JAN 2002, vol. 16, no. 1, January 2002 (2002-01), pages 44-52, XP002505316 ISSN: 0887-6924 * |
STUDNICKA G M ET AL: "HUMAN-ENGINEERED MONOCLONAL ANTIBODIES RETAIN FULL SPECIFIC BINDINGACTIVITY BY PRESERVING NON-CDR COMPLEMENTARITY-MODULATING RESIDUES" PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 7, no. 6, 1 June 1994 (1994-06-01), pages 805-814, XP000447301 ISSN: 0269-2139 * |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US10472623B2 (en) | 2008-04-11 | 2019-11-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9890377B2 (en) | 2008-04-11 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US11371039B2 (en) | 2008-04-11 | 2022-06-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US11359194B2 (en) | 2008-04-11 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US9017683B2 (en) | 2009-05-01 | 2015-04-28 | The University Of Tokyo | Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo |
US8455249B2 (en) | 2009-05-01 | 2013-06-04 | The University Of Tokyo | Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo |
WO2010126137A1 (fr) | 2009-05-01 | 2010-11-04 | 国立大学法人 東京大学 | Anticorps anti-cadhérine |
WO2011089211A1 (fr) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anticorps anti-cd133 et leurs procédés d'utilisation |
US11959118B2 (en) | 2010-05-27 | 2024-04-16 | Merck Sharp & Dohme Llc | Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc-region |
US10858686B2 (en) | 2010-05-27 | 2020-12-08 | Merck Sharp & Dohme Corp. | Method for preparing antibodies having improved properties |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
US10738111B2 (en) | 2014-12-19 | 2020-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US10000560B2 (en) | 2014-12-19 | 2018-06-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US11454633B2 (en) | 2014-12-19 | 2022-09-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
US11180548B2 (en) | 2015-02-05 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Methods of neutralizing IL-8 biological activity |
US10519229B2 (en) | 2015-02-05 | 2019-12-31 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding IL-8 antibodies |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
US11780912B2 (en) | 2016-08-05 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of IL-8 related diseases |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
US10844113B2 (en) | 2016-09-16 | 2020-11-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
US11780908B2 (en) | 2016-09-16 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use |
US10604561B2 (en) | 2016-09-16 | 2020-03-31 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
US20210369854A1 (en) * | 2017-11-29 | 2021-12-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd5+ cells |
US11891432B2 (en) | 2018-03-15 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use |
WO2019234576A1 (fr) | 2018-06-03 | 2019-12-12 | Lamkap Bio Beta Ltd. | Anticorps bispécifiques dirigés contre ceacam5 et cd47 |
US11555071B2 (en) | 2018-06-03 | 2023-01-17 | Lamkap Bio Beta Ltd. | Bispecific antibodies against CEACAM5 and CD47 |
US20210355230A1 (en) * | 2018-07-23 | 2021-11-18 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
WO2021110647A1 (fr) | 2019-12-02 | 2021-06-10 | Lamkap Bio Beta Ag | Anticorps bispécifiques dirigés contre ceacam5 et cd47 |
EP3831849A1 (fr) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Anticorps bispécifiques contre ceacam5 et cd47 |
EP3915641A1 (fr) * | 2020-05-27 | 2021-12-01 | International-Drug-Development-Biotech | Anticorps anti-cd5 et leurs procédés d'utilisation |
WO2022056459A1 (fr) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions et méthodes pour la modification du cd5 |
WO2022127844A1 (fr) * | 2020-12-17 | 2022-06-23 | 江苏先声药业有限公司 | Anticorps cd5 et son utilisation |
US11753481B2 (en) | 2020-12-18 | 2023-09-12 | Lamkap Bio Beta Ltd | Bispecific antibodies against CEACAM5 and CD47 |
WO2022130348A1 (fr) | 2020-12-18 | 2022-06-23 | Lamkap Bio Beta Ag | Anticorps bispécifiques dirigés contre ceacam5 et cd47 |
WO2022152185A1 (fr) * | 2021-01-12 | 2022-07-21 | 南京驯鹿医疗技术有限公司 | Anticorps entièrement humanisé ciblant cd5 |
CN113105547B (zh) * | 2021-05-18 | 2022-04-08 | 福州迈新生物技术开发有限公司 | 抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用 |
CN113105547A (zh) * | 2021-05-18 | 2021-07-13 | 福州迈新生物技术开发有限公司 | 抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用 |
WO2023242351A1 (fr) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Polythérapie d'anticorps bispécifiques dirigés contre ceacam5 et cd47 et anticorps bispécifiques dirigés contre ceacam5 et cd3 |
WO2024040195A1 (fr) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditionnement pour l'ingénierie de cellules immunitaires in vivo |
WO2024040194A1 (fr) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditionnement pour l'ingénierie de cellules immunitaires in vivo |
Also Published As
Publication number | Publication date |
---|---|
WO2008121160A3 (fr) | 2009-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11618788B2 (en) | Optimized antibodies that target CD19 | |
US8551485B2 (en) | Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells | |
US9040042B2 (en) | Optimized antibodies that target HM1.24 | |
AU2008207898B2 (en) | Optimized CD40 antibodies and methods of using the same | |
US20080260731A1 (en) | Optimized antibodies that target cd19 | |
US20080254027A1 (en) | Optimized CD5 antibodies and methods of using the same | |
US20080199471A1 (en) | Optimized cd40 antibodies and methods of using the same | |
WO2008121160A2 (fr) | Anticorps optimisés qui ciblent cd5 | |
WO2008091798A2 (fr) | Anticorps de ca9 optimises et methodes d'utilisation associees | |
WO2008098115A2 (fr) | Anti-corps igf-1r optimisés et procédés utilisant ceux-ci | |
US20080152649A1 (en) | Optimized igf-1r antibodies and methods of using the same | |
AU2011203503B2 (en) | Optimized antibodies that target CD19 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07873582 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07873582 Country of ref document: EP Kind code of ref document: A2 |